Treatment of Hypokalemia and Hyperkalemia

Therapy in Nephrology & Hypertension

Volumn , Issue , 2008, Pages 353-367

  Kamel, Kamel S ^a,b   Oh, Man S ^c   Lin, Shih Hua ^d   Halperin, Mitchell L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882490933     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605484-9.50032-0     Document Type: Chapter

References (66)

1. Kamel KS, Davids MR, Lin S-H, Halperin ML Interpretation of electrolytes and acid-base parameters in blood and urine. Brenner and Rector-s The Kidney 2007, vol 1:749-774. WB Saunders, Philadelphia. 8th ed. B.M. Brenner (Ed.).
2. Halperin ML, Kamel KS Potassium. Lancet 1998, 352:135-142.
3. Clausen T, Everts ME Regulation of the Na,K-pump in skeletal muscle. Kidney Int 1989, 35:1-13.
4. Counillon LL, Pouyssegur RJ The members of the Na+/H+ exchanger gene family: Their structure, function, expression, and regulation. The Kidney: Physiology & Pathophysiology 2000, vol 1:223-234. Lippincott Williams & Wilkins, Philadelphia. D.W. Seldin, G. Giebisch (Eds.).
5. Giebisch G, Malnic G, Berliner R Control of renal potassium excretion. Brenner and Rector-s The Kidney 1996, vol 1:371-407. WB Saunders, Philadelphia. 5th ed. B.M. Brenner (Ed.).
6. Rossier BC Cum grano salis: The epithelial sodium channel and the control of blood pressure. J Am Soc Nephrol 1997, 8:980-992.
7. Halperin ML, Kamel KS Dynamic interactions between integrative physiology and molecular medicine: The key to understand the mechanism of action of aldosterone in the kidney. Can J Physiol Pharmacol 2000, 78:587-594.
8. Kamel KS, Quaggin S, Scheich A, Halperin ML Disorders of potassium homeostasis: An approach based on pathophysiology. Am J Kidney Dis 1994, 24:597-613.
9. Funder JW 11β-Hydroxysteroid dehydrogenase and the meaning of life. Mol Cell Endocrinol 1990, 68:C3-C5.
10. Edwards CRW Lessons from licorice. N Engl J Med 1991, 24:1242-1243.
11. Carlisle EJF, Donnelly SM, Ethier J, et al. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int 1991, 39:1206-1212.
12. Schambelan M, Sebastian A, Rector FC Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption. Kidney Int 1981, 19:716-727.
13. Kahle KT, Wilson FH, Lalioti M, et al. WNK kinases: Molecular regulators of integrated epithelial ion transport. Curr Opin Nephrol Hypertens 2004, 557-562.
14. Schaefer M, Link J, Hannemann L, Rudolph KH Excessive hypokalemia and hyperkalemia following head injury. Intensive Care Med 1995, 21:235-237.
15. Lin SH, Lin YF, Halperin ML Hypokalemia and paralysis. Q J Med 2001, 94:133-139.
16. Al-Alazami M, Lin S, Chih-Jen C, et al. Unusual causes of hypokalaemia and paralysis. Q J Med 2006, 99:181-192.
17. Lin SH, Lin YF Propranolol rapidly reverses paralysis, hypokalemia and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis 2001, 37:620-624.
18. Lin S-H, Halperin ML Hypokalemia: A practical approach to diagnosis and its genetic basis. Clin Med Chem 2007, 14:1551-1565.
19. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
20. Kamel KS, Oh MS, Halperin ML Bartter-s, Gitelman-s, and Gordon-s syndromes: From physiology to molecular biology and back, yet still some unanswered questions. Nephron 2002, 92:18-27.
21. Vasuvattakul S, Quaggin SE, Scheich AM, et al. Kaliuretic response to aldosterone: Influence of potassium in the diet. Am J Kidney Dis 1993, 21:152-160.
22. Tannen RL Diuretic-induced hypokalemia. Kidney Int 1985, 28:988-1000.
23. Meria P, Kempf BF, Hermieu JF, et al. Laparoscopic management of primary hyperaldosteronism: Clinical experience with 212 cases. J Urol 2003, 169:32-35.
24. Sawka AM, Young WF, Thompson GB, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258-261.
25. Ghose RP, Hall PM, Bravo EL Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131:105-108.
26. Wang WH Regulation of renal K transport by dietary K intake. Annu Rev Physiol 2004, 66:547-569.
27. Cheema-Dhadli S, Lin S-H, Chong CK, et al. Requirements for a high rate of potassium excretion in rats consuming a low electrolyte diet. J Physiol Lond 2006, 572.2:493-501.
28. Kamel KS, Harvey E, Douek K, Halperin ML Studies on the pathogenesis of hypokalemia in Gitelman-s syndrome: Role of bicarbonaturia and hypomagnesemia. Am J Nephrol 1998, 18:42-49.
29. Nusing RM, Seyberth HW The role of cyclooxygenases and prostanoid receptors in furosemide-like salt losing tubulopathy: The hyperprostaglandin E syndrome. Acta Physiol Scand 2004, 181:523-528.
30. Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992, 116:813-820.
31. Warnock DG Liddle-s syndrome: 30 years later. J Nephrol 1993, 6:142-148.
32. Funder JW, Pearce PT, Smith R, Smith AI Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1998, 242:583-585.
33. Blumberg A, Weidmann P, Shaw S, Gnadinger M Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med 1988, 85:507-512.
34. Allon M, Copkney C Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990, 38:869-872.
35. Allon M, Shanklin N Effect of bicarbonate administration on plasma potassium in dialysis patients: Interactions with insulin and albuterol. Am J Kidney Dis 1996, 28:508-514.
36. Lens XM, Montoliu J, Cases A, et al. Treatment of hyperkalemia in renal failure: Salbutamol v. insulin. Nephrol Dial Transplant 1989, 4:228-232.
37. Conte G, Dal Canton A, Imperatore P, et al. Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure. Kidney Int 1990, 38:301-307.
38. Montoliu J, Lens XM, Revert L Potassium-lowering effect of albuterol for hyperkalemia in renal failure. Arch Intern Med 1987, 147:713-717.
39. Liou HH, Chiang SS, Wu SC, et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure. Am J Kidney Dis 1994, 23:266-270.
40. Allon M, Dunlay R, Copkney C Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med 1989, 110:426-429.
41. Blumberg A, Weidmann P, Ferrari P Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992, 41:369-374.
42. Guttierez R, Schlessinger F, Oster JR, et al. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab 1991, 17:297-302.
43. Schwarz KC, Cohen BD, Lubash GD, Rubin AL Severe acidosis and hyperpotassemia treated with sodium bicarbonate infusion. Circulation 1959, 19:215-220.
44. Kim HJ Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron 1996, 72:476-482.
45. Emmett M, Hootkins RE, Fine KD Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion. Gastroenterology 1995, 108:752-760.
46. Johnson LR Fluid and electrolyte absorption. Gastrointestinal Physiology 1997, 135-145. Mosby-Yearbook, Philadelphia. 5th ed. L.R. Johnson (Ed.).
47. Sandle GI, Gaiger E, Tapster S, Goodsphip THJ Evidence for large intestinal control of potassium homeostasis in uremic patients undergoing long term dialysis. Clin Sci 1987, 73:247-252.
48. Martin RS, Panease S, Virginillo M, et al. Increased secretion of potassium in the rectum of man with chronic renal failure. Am J Kidney Dis 1986, 8:105-110.
49. Agarwal R, Afzalpurkar R, Fordtran J Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 1994, 107:548-571.
50. Flinn RB, Merrill JP, Welzant WR Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol. N Engl J Med 1961, 264:111-115.
51. Scherr L, Ogden DA, Mead AW Management of hyperkalemia with a cation-exchange resin. N Engl J Med 1961, 264:115-119.
52. Gruy-Kapral C, Emmett M, Santa Ana CA Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998, 9:1924-1930.
53. Gerstman BB, Kirkman P, Platt R Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992, 20:159-161.
54. Kamel KS, Lin S-H, Halperin ML Clinical disorders of hyperkalemia. The Kidney 2008, vol 1:1387-1405. Raven Press, New York. R. Alpern, S.C. Hebert (Eds.).
55. Wilson FH, Disse-Nocodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
56. Kaiser UB, Ethier JH, Kamel KS, Halperin ML Persistent hyperkalemia in a patient with diabetes mellitus: Presumptive evidence for a chloride shunt type of disorder. Clin Invest Med 1992, 15:187-193.
57. Kamel K, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporin. J Am Soc Nephrol 1992, 2:1279-1284.
58. Choi MJ, Fernandez PC, Patnaik A, et al. Trimethoprim induced hyperkalemia in a patient with AIDS. N Engl J Med 1993, 328:703-706.
59. Schreiber MS, Chen C-B, Lessan-Pezeshki M, et al. Antikaliuretic action of trimethoprim is minimized by raising urine pH. Kidney Int 1996, 49:82-87.
60. Orth DN, Kovacs WJ The adrenal cortex. Williams Textbook of Endocrinology 1998, 550. WB Saunders, Philadelphia. 9th ed. J.D. Wilson, D.W. Foster, H.M. Kronenberg, P.R. Larsen (Eds.).
61. Gagnon RF, Halperin ML Possible mechanisms to explain the absence of hyperkalemia in a patient with Addison-s disease. Nephrol Dial Transplant 2001, 16:1280-1284.
62. Al-Alazami M, Lin S, Chih-Jen C, et al. Unusual causes of hypokalaemia and paralysis. Q J Med 2006, 99:181-192.
63. Kamel KS, Davids MR, Lin S-H, Halperin ML Interpretation of electrolytes and acid-base parameters in blood and urine. Brenner and Rector-s The Kidney 2007, Vol. 1:749-774. WB Saunders, Philadelphia. 8th ed. B.M. Brenner (Ed.).
64. Kamel KS, Lin S-H, Halperin ML Clinical disorders of hyperkalemia. The Kidney 2008, vol 1:1387-1405. Raven Press, New York. R. Alpern, S.C. Herbert (Eds.).
65. Kamel KS, Wei C Controversial issues in treatment of hyperkalemia. Nephrol Dial Transplant 2003, 18:2215-2218.
66. Lin SH, Lin YF, Halperin ML Hypokalemia and paralysis. Q J Med 2001, 94:133-139.